Topic Hub
6 clinically reviewed articles, written and peer-reviewed by the HealthRX Medical Team.
Explore
Showing 6 of 6 clinical reviews.
A deep clinical review of the methodology flaws, enrollment biases, generalizability gaps, statistical caveats, and conflict-of-interest concerns that qualify the ORIGIN trial's neutral cardiovascular findings for insulin glargine in dysglycemia.
Read clinical reviewA detailed breakdown of the ORIGIN trial's randomization, blinding, endpoint adjudication, comparator rationale, and statistical framework, and why each design choice matters for interpreting cardiovascular safety of insulin glargine in early dysglycemia.
Read clinical reviewDeep dive into the ORIGIN trial follow-up: long-term outcomes after insulin glargine vs standard care in early dysglycemia, durability of glycemic effects, and cardiovascular safety signals over extended observation.
Read clinical reviewHealth-economic analyses from the ORIGIN trial examining cost per QALY of insulin glargine vs standard care in early dysglycemia, payer implications, and value calculations for patients.
Read clinical reviewA plain-English deep dive into the ORIGIN trial, which tested whether early insulin glargine could prevent cardiovascular events in people with dysglycemia. Full methodology, results, and clinical implications.
Read clinical reviewHow the ORIGIN trial's neutral cardiovascular findings for insulin glargine reshaped guidelines, prescribing behavior, and risk conversations for early dysglycemia management.
Read clinical review